Compare PROK & AIBZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROK | AIBZ |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.6M | 337.2M |
| IPO Year | 2021 | N/A |
| Metric | PROK | AIBZ |
|---|---|---|
| Price | $1.56 | $8.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.40 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 730.2K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $893,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1075.00 | N/A |
| 52 Week Low | $1.53 | $6.13 |
| 52 Week High | $4.05 | $9.91 |
| Indicator | PROK | AIBZ |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 44.71 |
| Support Level | N/A | $6.17 |
| Resistance Level | $2.59 | $9.63 |
| Average True Range (ATR) | 0.17 | 0.99 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 2.86 | 54.23 |
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.